HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorEastern Hepatobiliary Surgery Hospital
About this trial
Intrahepatic cholangiocarcinoma (ICC) has a poor prognosis. The aim of this study is to investigate the efficacy and safety of GP-HAIC combined with immunosuppressants in the treatment of initially unresectable ICC patients, as well as its role in conversion therapy. A prospective study was conducted on the data of locally advanced unresectable ICC patients receiving GC-HAIC combined with immunosuppressive therapy, evaluating the treatment efficacy and safety.
Eligibility criteria
Qualifiers
Age: Age ≥ 18 years old.
Diagnosis: Advanced unresectable intrahepatic cholangiocarcinoma (ICC) diagnosed by histology or imaging.
Measurable lesion: At least one measurable tumor lesion (according to RECIST 1.1 criteria).
Physical fitness status: The Eastern Cancer Collaboration Group (ECOG) physical fitness status score is 0 or 1.
Disqualifiers
Previous treatment: Previously received systemic treatment for ICC.
Poor physical condition: ECOG physical condition score ≥ 2.
Poor liver function: Child Pugh grading>8.
Short life expectancy: Life expectancy is less than 3 months.
Trial design
Treatments tested in this trial
- PD-L1 inhibitor
- HAIC
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov